New inhaled drug could ease breathing for PAH patients
NCT ID NCT07481981
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial is testing whether a once-daily inhaled medication called treprostinil palmitil can help adults with pulmonary arterial hypertension (PAH) walk farther. About 344 participants will receive either the drug or a placebo for 24 weeks. The main goal is to see if the drug improves the distance they can walk in six minutes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
treprostinil palmitil inhalation powder
What this could lead to
If successful, this could provide a more convenient once-daily inhaled treatment option to help people with pulmonary arterial hypertension walk farther and manage their condition.
What could go wrong
This is a phase 3 trial, but the drug is still experimental. It may not improve exercise capacity more than placebo, and side effects from the inhaled medication could occur.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
USA007
RECRUITINGAnderson, South Carolina, 29621, United States
-
USA008
RECRUITINGSanta Barbara, California, 93105, United States